Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer

NCT00052949 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

NIH

Sponsor class

Conditions

Recurrent Small Cell Lung Cancer

Interventions

DRUG: imatinib mesylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]